We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




ECCMID Congress Name Changes to ESCMID Global

By LabMedica International staff writers
Posted on 11 Apr 2024
Print article
Image: ESCMID has modernized its branding and communications (Photo courtesy of ESCMID)
Image: ESCMID has modernized its branding and communications (Photo courtesy of ESCMID)

Over the last few years, the European Society of Clinical Microbiology and Infectious Diseases (ESCMID, Basel, Switzerland) has evolved remarkably. The society is now stronger and broader than ever before in the four decades since it was founded. Currently, ESCMID is focusing on stepping up the fight against antimicrobial resistance, advancing preparedness for emerging infections, and leading in the practice, education, and training of specialists. In recent years, ESCMID has welcomed over 4000 new members and expects to see a record-breaking 20,000 colleagues attend its congress in Barcelona. Hence, the organization feels the need to adapt to this new reality.

In 2023, ESCMID’s in-depth analysis of its brand and communication efforts revealed that the brand failed to adequately reflect ESCMID’s expanding global role. The analysis also revealed that most community members were unaware of various activities undertaken by ESCMID related to research, education, and guidelines. Additionally, most of its audience was unaware of the connection between the European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) and ESCMID. As a result, the society has now decided to strengthen its main brand, ESCMID, and bring all of its various sub-brands more closely together under one large ESCMID umbrella. This includes changing the name of its congress to “ESCMID Global”, creating a clear link to ESCMID, and conveying its outreach and perspective beyond Europe.

Simultaneously, ESCMID is modernizing its visual identity. As the society strives for pioneering research and state-of-the-art education, it also aims to communicate in an effective manner that will be suitable to the present time and also apt for the next decade. As a first step in these efforts, the organization has released its renewed website escmid.org. The upcoming ESCMID Global, formerly ECCMID, in Barcelona (27–30 April 2024) will be the society’s 34th congress and the first one with the new name and look.

Related Links:
ESCMID

New
Gold Member
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Gold Member
Troponin T QC
Troponin T Quality Control
New
Zonulin ELISA
IDK Zonulin (Serum) ELISA
New
Silver Member
CEA Assay
Carcinoembryonic Antigen Assay

Print article

Channels

Immunology

view channel
Image: Example image of the high-throughput microscopy method used in the study, showing immune cells stained with different fluorescence markers (Photo courtesy of Felix Kartnig/CeMM, MedUni Vienna)

Cutting-Edge Microscopy Technology Enables Tailored Rheumatology Therapies

Rheumatoid arthritis is the most common inflammatory joint disorder, with women three times as likely to suffer from the condition as men. Treatment advances made over the past decades have led to the... Read more

Microbiology

view channel
Image: RNA sequencing directly from whole blood aims to expand access to LRTI testing (Photo courtesy of CARB-X)

Novel Test to Diagnose Bacterial Pneumonia Directly from Whole Blood

Pneumonia and lower-respiratory-tract infections (LRTIs) are among the top causes of illness and death globally, particularly in vulnerable populations such as the elderly, young children, and immunocompromised... Read more

Pathology

view channel
Image: Lunit SCOPE HER2 is an AI-powered solution designed to detect HER2 expression profile (Photo courtesy of Lunit)

AI-Powered Pathology Solutions Accurately Predict Outcomes for HER2-Targeted Therapy in Metastatic CRC

A new study has highlighted how artificial intelligence (AI)-powered analysis of HER2 and the tumor microenvironment (TME) can improve patient stratification and predict clinical outcomes more effectively.... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.